✦ LIBER ✦

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations

✍ Scribed by Eva Wardelmann; Nadja Thomas; Sabine Merkelbach-Bruse; Katharina Pauls; Nicola Speidel; Reinhard Büttner; Heiner Bihl; Claudia C Leutner; Thomas Heinicke; Peter Hohenberger

Book ID: 117783472
Publisher: The Lancet
Year: 2005
Tongue: English
Weight: 163 KB
Volume: 6
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(05)70097-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Resistance to imatinib, low-grade FDG-av

Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour

✍ Florian Grimpen; Desmond Yip; Grant McArthur; Paul Waring; David Goldstein; Maur 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 260 KB

A new mutation in the KIT ATP pocket cau

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

✍ Elena Tamborini; Lorena Bonadiman; Angela Greco; Veronica Albertini; Tiziana Neg 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 241 KB

Late resistance to imatinib therapy in a

Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation

✍ Wakai, T; Kanda, T; Hirota, S; Ohashi, A; Shirai, Y; Hatakeyama, K 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 116 KB

KIT mutations and dose selection for ima

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

✍ Maria Debiec-Rychter; Raf Sciot; Axel Le Cesne; Marcus Schlemmer; Peter Hohenber 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 268 KB

Pathological response of gastrointestina

Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones

✍ M B Loughrey; V Beshay; A Dobrovic; J Zalcberg; P M Waring 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB

Surgical Management After Neoadjuvant Im

Surgical Management After Neoadjuvant Imatinib Therapy in Gastrointestinal Stromal Tumours (GISTs) with Respect to Imatinib Resistance Caused by SecondaryKITMutations

✍ Florian Haller; Sven Detken; Hans-Jürgen Schulten; Nicole Happel; Bastian Gunawa 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 271 KB